Introduction
============

According to past work ([@B2]), three mechanisms have been described for plasmid- mediated quinolone resistance: *qnr* determinants ([@B13]; [@B14]; [@B17]; [@B20]), aminoglycoside acetyltransferase *aac(6′)- Ib-cr* ([@B17]), and the *qepA* and *oqxAB* eﬄux pump genes, which confer decreased susceptibility to quinolones ([@B16]; [@B23]; [@B22]). The *qepA1* gene was first investigated in 2007 by two groups from Japan and Belgium ([@B16]; [@B23]). In 2008, the *qepA2* was discovered by a French research group ([@B2]). Currently, both the *qepA1* and *qepA2* genes have been reported worldwide ([@B11]; [@B15]; [@B6]; [@B19]; [@B3]). Recently, we identified a new *qepA* allele *qepA3* from in a Chinese patient (GenBank with accession number JQ064560). Although the human *qepA* has a fairly low prevalence in Korea ([@B8]; [@B15]), it is commonly found in *Enterobacteriaceae* isolates from food- producing animals in China ([@B11]; [@B12]; [@B3]). Therefore, more surveillance is needed for *Enterobacteriaceae* harboring the *qnr*, *aac(6′)-Ib-cr* and *qepA*.

In this study, we investigated the *qepA* gene in 656 *Enterobacteriaceae* isolates from hospitalized patients and only 13 isolates were found positive. This result confirm that *qepA* has low prevalence (1.98%) (0.91% for *qepA1*, 0.31% for *qepA2* and 0.76% for *qepA3*) in patients of our area. However, five isolates were determined to harbor novel *qepA3* structures. These structure were characterized to provide better understanding of the gene for potential management of plasmid-mediated antibiotic resistance.

Materials and Methods {#s1}
=====================

Bacterial Strains and Luria-Bertani (LB) Agar Plates
----------------------------------------------------

*Enterobacteriaceae* isolates EC3157, EC3587, CD4359, KP3764, and ECL3786 were identified using the Vitek 2 system (bioMérieux, France) according to the manufacturer's instructions. *Escherichia co*li isolates EC3157 and EC3587 were isolated from the blood and sputum samples of ICU inpatients, respectively. CD4359, an isolate of *Citrobacter koseri*, was obtained from the sputum of an inpatient in Infection Unit, while KP3764, an isolate of *Klebsiella pneumoniae*, was from a blood sample of an ICU inpatient. ECL3786, an isolate of *Enterobacter cloacae*, was from the chest wound secretions of a cardiothoracic surgical inpatient. *E. coli JM109* was used as the host for cloning and an azide-resistant *E. coli* (strain J53) was used as the recipient strain for conjugation experiments. The LB1 agar medium for plasmid transformation contained 100 μL of isopropyl β-[D]{.smallcaps}-1-thiogalactopyranoside (IPTG, 24 mg/mL), 200 μL of 5-bromo-4-chloro- 3-indolyl β-[D]{.smallcaps}-galactopyranoside (X-Gal, 20 mg/mL) and 100 μL of ampicillin (Amp, 100 mg/mL) in 100 mL medium. LB2 agar plates were used for conjugation experiments and were supplemented with sodium azide (150 μg/mL) and ciprofloxacin (0.25 μg/mL).

Susceptibility Testing
----------------------

The minimum inhibitory concentrations (MICs) of eight antimicrobial agents (nalidixic acid, ofloxacin, ciprofloxacin, cefotaxime, ceftazidime, amikacin, and gentamicin) were determined using the MicroScan microdilution panel (Scott, USA) broth dilution method. *E. coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as the controls. The results were interpreted according to the CLSI guidelines ([@B4]).

Plasmid Isolation and Sequence Analysis
---------------------------------------

Bacterial plasmid DNA was extracted using a plasmid extraction kit (TaKaRa, Japan) according to the manufacturer's instructions. PCR amplifications were preformed using primers based on the pHPA (**Table [1](#T1){ref-type="table"}**, [@B23]). PCR was run for 3 min at 94°C followed by 30 cycles of 1 min of denaturing at 94°C and annealing at 56.9°C, with a final elongation of 10 min at 72°C on Life Veriti^®^ PCR machine (Invitrogen, USA). The total reaction volume was 20 μl containing 4 μL 5X PCR buffer, 0.4 μL of 10 mM dNTPs, 1 μL each of 10 μM primers and 0.2 μL Polymerase, with nuclease-free water filled up to 20 μL, and bacterial plasmids harboring the *qepA* gene as template. The amplicons were digested with *Dra*I and *Bam*HI (TaKaRa, Japan), ligated to linearized pMD19-T (TaKaRa, Japan), and transformed into *E. coli* JM109 competent cells. Plasmids DNA from Amp resistant colonies recovered on LB1 plate were sequenced.

###### 

Primers used for PCR and sequencing.

  Primer              Sequence (5′-3′)   Reference                   
  ------------------- ------------------ --------------------------- ------------
  tnpR                F                  CGACACTGCCGATATGATCC        [@B15]
                      R                  CGGGCAATACTGAGCTGATG        
  TEM                 F                  ATAAAATTCTTGAAGACGAAA       [@B10]
                      R                  GACAGTTACCAATGCTTAATC       
  rmtB                F                  CCCAAACAGACCGTAGAGGC        [@B9]
                      R                  CTCAAACTCGGCGGGCAAGC        
  qepA                F                  AGCAGCGCGCTGAATCCA          This study
                      R                  CGAACCCAGTGGACATAA          
  qepA (sequencing)   F                  AGC AGCGCGCTGAATCCA         This study
                      R                  CTTCCTGCCCGAGTA TCG TG      
  intI1               F                  GCCTTGCTGTTCTTCTACGG        [@B7]
                      R                  GATGCCTGCTTGTTCTACGG        
  tnpA                F                  GGCGGGATCTGCTTGTAGAG        [@B7]
                      R                  CTCCGGAGATGTCTGGCTTACT      
  dfr2                F                  TTGGGCTTCACCAGAGTATCAAGTT   [@B2]
                      R                  GCTGTGGACGGTGCCGCATGATTTG   
  CTX-M-14            F                  GAAAGAGAGTGCAACGGATG        This study
                      R                  ATTGGAAAGGGTTCATCACC        

Conjugation
-----------

The five isolates were conjugated with *E. coli* J53 as described previously ([@B21]). In the conjugation experiments, the isolates were used as donors and azide-resistant *E. coli* J53 as the recipient strain by filter mating. Transconjugants were selected on the LB2 agar plates. MICs for the donors, transconjugants, and recipients were also measured as described above.

Results
=======

Plasmid Isolation and Characterization
--------------------------------------

Plasmids were isolated from the five *Enterobacteriaceae* isolates and separated on 0.7% agarose gel by gel electrophoresis. Results showed that plasmids pKP3764, pECL3876, pEC3157, pEC3587, and pCD4359 from isolates KP3764, pECL3876, EC3157, EC3587, and CD4359 were estimated to be about 53 kb, 72 kb, 145, 152, and 168 kb, respectively (**Figure [1A](#F1){ref-type="fig"}**).

![**Electrophoresis of plasmids isolated from clinical isolates and the recombinant plasmids used for sequence analysis.** The left columns indicate the DNA markers while the right column denote the plasmid sizes. **(A)** Lane M1, a λ DNA marker (Amersham Biosciences, USA); Lanes 1--5, plasmids pKP3764, pECL3876, pEC3157, pEC3587, and pCD4359. **(B)** Lane M2, λ *Hind*III DNA marker (Amersham Biosciences, USA); Lanes 1--5, recombinant plasmids pECD2, pECD4, pCDD2, pKPD1, and pECLD1.](fmicb-06-01147-g001){#F1}

The *qep A*-containing sequences in the five strains were amplified, digested with *Dra*I and/or *Bam*HI and subcloned in pMD19-T to generate recombinant plasmids pECD1, pECD2, pECD3, pECD4, pCDD2, pKPD1, and pECLD1 (**Figure [1B](#F1){ref-type="fig"}**). The inserts in these plasmids were sequenced and analyzed for *qep A* and its flanking structures (GenBank accession numbers KR259130, KR259131, KR259132, KR259133, and KR259134, Supplementary Material) (**Figure [2](#F2){ref-type="fig"}**). The results showed that in addition to *qepA3*, which was present in all plasmids, the inserts from pEC3157 and pCD4359 contained the *bla*~CTX-M-14~ and *rmtB* genes; the inserts from pEC3587 had the *bla*~TEM-12~ gene; inserts from all plasmids except pCD4359 had the truncated *dfr2* gene; the inserts from pCD4539 contained the *bla*~TEM-1~ and *rmtB* genes; the insert from pKPD1 and pECLD1 contained truncated *dfr2* gene. No other resistant genes were found in these sequences.

![**Genetic structures surrounding the *qepA3* gene in pEC3157, pEC3587, pCD4359, pKP3764, and pECL3786.** The numbers in parentheses are GenBank accession numbers; "*ggatcc*" and "*tttaaa*" indicate restriction sites; Δ *(delta)* denotes truncated gene; Δ*intI1-groEL* denotes the truncated *intI1* and *groEL* fusion gene. The figures in the parentheses following the names of the plasmids denote the plasmid size.](fmicb-06-01147-g002){#F2}

Antibiotic Susceptibility
-------------------------

Through conjugation, the plasmids from the five isolates (donors) were transferred to *E. coli* J53 (recipients). The MIC values for cefotaxime and ceftazidime in the transconjugants with the isolates EC3157, EC3587, and CD4359 were much higher than those of the recipient *E. coli* J53 (**Table [2](#T2){ref-type="table"}**). Similarly, the MIC values for nalidixic acid, norfloxacin, ofloxacin, and ciprofloxacin in the transconjugants with the five isolates were generally higher than those of *E. coli* J53 (**Table [2](#T2){ref-type="table"}**). Contrastingly, the MIC values nalidixic acid, ofloxacin, ciprofloxacin, amikacin, and gentamicin in the transconjugant involving the EC3157, EC3587, CD4357, and ECL3786 were generally higher than those of *E. coli* J53 (recipient) (**Table [2](#T2){ref-type="table"}**). These results demonstrated that the antibiotic resistant genes are located in the plasmids.

###### 

Minimum inhibitory concentrations of antimicrobial agents for donors, transconjugants, and their recipients.

  Stain                            MIC (μg/mL)                                                 
  -------------------------------- ------------- ------ ------- ------- ------- ------- ------ -------
  **Donor**                                                                                    
  EC3157                           128           8      4       2       128     4       64     128
  EC3587                           128           16     4       4       32      4       128    \>128
  CD4359                           128           16     4       4       32      2       64     128
  KP3764                           128           8      4       2       0.25    0.25    0.50   0.125
  ECL3786                          32            8      2       2       0.125   0.125   64     128
  **Transconjugant**                                                                           
  EC3157*- Escherichia coli* J53   8             2      1       0.50    8       1       16     32
  EC3587*- E. coli* J53            16            4      1       1       4       1       32     64
  CD4359*- E. coli* J53            16            4      1       1       4       1       16     64
  KP3764*- E. coli* J53            16            2      1       0.50    0.125   0.125   0.50   0.063
  ECL3786*- E. coli* J53           8             2      0.50    0.50    0.063   0.125   16     32
  **Recipient**                                                                                
  *E. coli* J53                    4             0.25   0.032   0.016   0.063   0.25    0.50   0.063

NAL, nalidixicacid; OFL, ofloxacin; CIP, ciprofloxacin; CTX, cefotaxime; CAZ, ceftazidime; AMK, amikacin; GEN, gentamicin; NOR, norfloxacin.

Discussion
==========

Previous studies have shown that quinolone and fluoroquinolone resistance genes in *E. coli* and *Klebsiella* isolates are located on plasmids, which often carry other antimicrobial resistant genes, and can be transferred to other strains by conjugation or transformation ([@B19]). Since the discovery of *qepA1* and *qepA2* in 2007 and 2008, the genetic environment and location of the *qepA* genes in the plasmid pHPA have both been well-established ([@B16]; [@B23]; [@B2]). In this study, five *Enterobacteriaceae* isolates carrying the *qepA3* and surrounding genes were investigated, and are found to have different genetic structures (**Figure [2](#F2){ref-type="fig"}**) surrounding *qepA3.*

The plasmid pCD4359 from isolate CD4359 showed a similar structure to pHPA, except for the *qepA* allele and a truncated *dfr2*, a gene closely related to vertebrate FGF-receptor. The plasmids pEC3587 and pEC3157 were different from pHPA, where *bla*~TEM-1~ in pHPA was replaced by *bla*~TEM-12~ or *bla*~CTX-M-14~, respectively (**Figure [2](#F2){ref-type="fig"}**). *bla*~CTX-M-14~,*bla*~TEM-1,~ and *bla*~TEM-12~ code β-lactamase and are important determinants of drug resistance. In addition, in pCD4359, there is an additional *ΔintI1* downstream of the *rmtB which* confers high-level resistance to all aminoglycoside and missing *Δdfr2*. The sequence between IS*26* and *tnpR* was also truncated. Furthermore, *rmtB* or *ISCR3C* are not linked with *qepA3* directly in pKP3764 as reported previously ([@B16]; [@B23]; [@B2]; [@B8]; [@B18]; [@B1]).

In pEC3587, the *bla*~TEM-12~ gene took the place of *bla*~TEM-1~ and had a truncated *dfr2* gene as compared with pHPA. These results are also different from previous reports ([@B16]; [@B23]; [@B2]; [@B8]; [@B18]; [@B1]). Surprisingly, in pKP3764 there are three genes *qepA3*, truncated *dfr2*, and truncated *intI1-groEL* fusion gene between the two IS*26* insertions, while in pKP3764 and pECL3786, therefore are four genes: *rmtB*, *qepA3*, truncated *dfr2*, and truncated *intI1-groEL* fusion genes. To date, these genetic structures have not been identified in previous studies ([@B8]; [@B18]; [@B1]). Moreover, pKP3764 is the only plasmid that does not contain the *rmtB* gene among the five plasmids studied in this study. According to a previous report, 58.3% (28/48) of *rmtB*-positive *E. coli* isolates harbored the *qepA* gene ([@B5]). Whether or not these results suggest a strong link between *qepA* and *rmtB* remains to be investigated. In these five genetic structures (**Figure [2](#F2){ref-type="fig"}**), the *qepA3* gene and its downstream genes were nearly all identical except for the truncated *dfr2* deletion in pCD4359. After pEC3157 and pEC3587 were digested by the *Dra*I, the size of both products were identical at approximate 6.2 kb. It should be noted that it is also possible that the IS*CR3C* is not a stable link between IS*CR3C* and the *qepA* gene.

*QepA* gene is a quinolone pump gene that confers resistance to nalidixic acid and norfloxacin. Stains carrying the gene may be resistant or sensitive to ofloxacin and ciprofloxacin with increased MIC. In the conjugation experiments, we found that *E. coli* cells with pEC3587 and pCD4359 were resistant to penicillins and aminoglycoside antibiotics drugs such as amikacin, gentamicin, gentamicin, and tobramycin. They were tolerant or sensitive to ofloxacin and ciprofloxacin, but the MICs were increased. These results indicate that there might be synergistic effect against antibiotics when the *gepA*, *blaCTX-M 14*, and *rmtB* are present in the same plasmids, leading to multidrug resistance.

Taken together, our works suggest that there are sequence variations surrounding the *qepA3* even if a limited number of isolates are analyzed, and it is likely that more variations would exist that may impact the resistance profiles, and subsequently the clinical implications of the bacteria. More studies are needed to link these structure variation to resistance profiles and potential clinical outcomes.

Conclusion
==========

The novel genetic structures surrounding the *qepA3* gene have been discovered in the isolates obtained from five patients in China although the prevalence for the *qepA* allele in hospital patients are low. One of the isolates is linked to the non-*rmtB*- or non- IS*CR3C*- producing genetic structure in the *qepA3* genetic environment. Moreover, the *bla*~CTX-M-14~ or *bla*~TEM-12~ genes are found to be associated with the *qepA3* gene in these structures instead of the *bla*~TEM-1~ gene. These results provide new insight into the variation in genetic environments of the *qepA3* gene and would be useful for further investigation of the clinical implications in antibiotic resistance management.
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